BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Willard H. Dere sold 4,430 shares of BioMarin Pharmaceutical stock in a transaction on Friday, June 26th. The stock was sold at an average price of $123.61, for a total value of $547,592.30. Following the sale, the director now owns 13,290 shares in the company, valued at $1,642,776.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
BMRN opened at $123.34 on Wednesday. The firm has a market capitalization of $22.09 billion, a P/E ratio of 200.29 and a beta of 1.04. BioMarin Pharmaceutical Inc. has a one year low of $62.88 and a one year high of $124.95. The company has a fifty day moving average price of $106.97 and a 200-day moving average price of $91.70. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.58 and a quick ratio of 1.72.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.32. The company had revenue of $502.07 million during the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a return on equity of 3.62% and a net margin of 6.31%. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.32) earnings per share. On average, analysts expect that BioMarin Pharmaceutical Inc. will post 0.43 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of BMRN. Chevy Chase Trust Holdings Inc. bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter worth approximately $25,000. Orion Portfolio Solutions LLC bought a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth $26,000. Signaturefd LLC raised its position in shares of BioMarin Pharmaceutical by 43.1% during the 1st quarter. Signaturefd LLC now owns 382 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. Shine Investment Advisory Services Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 199.5% during the 1st quarter. Shine Investment Advisory Services Inc. now owns 602 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 401 shares during the last quarter. Finally, CI Investments Inc. grew its position in BioMarin Pharmaceutical by 851.2% in the fourth quarter. CI Investments Inc. now owns 780 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 698 shares in the last quarter. 96.46% of the stock is owned by institutional investors.
BMRN has been the topic of a number of research reports. Morgan Stanley lifted their price target on shares of BioMarin Pharmaceutical from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Barclays boosted their target price on BioMarin Pharmaceutical from $105.00 to $125.00 in a research note on Friday, June 5th. Credit Suisse Group reaffirmed a “buy” rating and set a $128.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, June 1st. Bank of America lifted their price objective on BioMarin Pharmaceutical from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Oppenheimer upped their price objective on shares of BioMarin Pharmaceutical from $88.00 to $95.00 and gave the company a “performer” rating in a report on Thursday, June 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $116.62.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.